Correlation between KRAS Mutation and CTLA-4 mRNA Expression in Circulating Tumour Cells: Clinical Implications in Colorectal Cancer
Genes · 16.09.2023 · 14 (9) · 1808
DOI: 10.3390/genes14091808 ↗Kurz gefasst
Fachartikel in der Zeitschrift Genes, online erschienen am 16.09.2023. Verfasst von Sharmin Aktar und 12 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Molecular Pathology, School of Medicine and Dentistry, Griffith University, Gold Coast, QLD 4222, Australia. Hauptthemen laut MEDLINE: Neoplastic Cells, Circulating, Colorectal Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Combination strategies of KRAS inhibition with immunotherapy in treating advanced or recurrent colorectal carcinoma (CRC) may need to be assessed in circulating tumour cells (CTCs) to achieve better clinical outcomes. This study aimed to investigate the genomic variations of KRAS in CTCs and matched CRC tissues and compared mRNA expression of KRAS and CTLA-4 between wild-type and KRAS-mutated CTCs and CRC tissues. Clinicopathological correlations were also compared. Six known mutations of KRAS were identified at both codon 12 and codon 13 (c.35G>T/G12V, c.35G>A7/G12D, c.35G>C/G12A, c.34G>A/G12S, c.38G>C/G13A, and c.38G>A/G13D). Three CTC samples harboured the identified mutations (16.7%; 3/18), while fifteen matched primary tumour tissues (65.2%, 15/23) showed the mutations. CTCs harbouring the KRAS variant were different from matched CRC tissue. All the mutations were heterozygous. Though insignificant, CTLA-4 mRNA expression was higher in patients carrying KRAS mutations. Patients harbouring KRAS mutations in CTCs were more likely to have poorly differentiated tumours (p = 0.039) and with lymph node metastasis (p = 0.027) and perineural invasion (p = 0.014). KRAS mutations in CTCs were also significantly correlated with overall pathological stages (p = 0.027). These findings imply the genetic basis of KRAS with immunotherapeutic target molecules based on a real-time platform. This study also suggests the highly heterogeneous nature of cancer cells, which may facilitate the assessment of clonal dynamics across a single patient’s disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cancer Molecular Pathology, School of Medicine and Dentistry, Griffith University, Gold Coast, QLD 4222, Australia.
- Menzies Health Institute Queensland, Griffith University, Gold Coast, QLD 4222, Australia.
- Department of Biochemistry and Molecular Biology, Mawlana Bhashani Science and Technology University, Tangail 1902, Bangladesh.
- Department of Biochemistry and Molecular Biology, University of Rajshahi, Rajshahi 6205, Bangladesh.
- Faculty of Health Sciences & Medicine, Bond University, Gold Coast, QLD 4229, Australia.
- Department of Biochemistry & Biotechnology, University of Barishal, Barishal 8254, Bangladesh.
ORCID-Profile: Sharmin Aktar, Indra Neil Choudhury, Md Sajedul Islam, Ichiro Abe, Vinod Gopalan, Alfred K Lam
Zitieren
APA
Aktar, S., Islam, F., Cheng, T., Gamage, S. M. K., Choudhury, I. N., Islam, M. S., Lu, C. T., Hamid, F. B., Ishida, H., Abe, I., Xie, N., Gopalan, V., & Lam, A. K. (2023). Correlation between KRAS Mutation and CTLA-4 mRNA Expression in Circulating Tumour Cells: Clinical Implications in Colorectal Cancer. Genes, 14(9), 1808. https://doi.org/10.3390/genes14091808
Vancouver
Aktar S, Islam F, Cheng T, Gamage SMK, Choudhury IN, Islam MS, et al. Correlation between KRAS Mutation and CTLA-4 mRNA Expression in Circulating Tumour Cells: Clinical Implications in Colorectal Cancer. Genes. 2023;14(9):1808. doi:10.3390/genes14091808
BibTeX
@article{Aktar2023,
author = {Aktar, Sharmin and Islam, Farhadul and Cheng, Tracie and Gamage, Sujani Madhurika Kodagoda and Choudhury, Indra Neil and Islam, Md Sajedul and Lu, Cu Tai and Hamid, Faysal Bin and Ishida, Hirotaka and Abe, Ichiro and Xie, Nan and Gopalan, Vinod and Lam, Alfred K},
title = {Correlation between KRAS Mutation and CTLA-4 mRNA Expression in Circulating Tumour Cells: Clinical Implications in Colorectal Cancer},
journal = {Genes},
year = {2023},
volume = {14},
number = {9},
pages = {1808},
doi = {10.3390/genes14091808}
}
EUVIMED